Why did AORT's EPS trend change in 2024?

Artivion's EPS trend change in 2024 can be attributed to a combination of factors:

1. **Revenue Shortfall in Q4**: The most significant factor contributing to the EPS trend change was Artivion's Q4 revenue shortfall. The company reported zero adjusted earnings per share on $97.3 million of revenues, which trailed the expected $0.04 in adjusted EPS on $100.8 million of revenues. This missed expectation resulted in a substantial decline in EPS, as the company's profitability fell short of analysts' forecasts.
2. **Operational Disruptions**: A cybersecurity incident that occurred in late November 2024 caused operational disruptions, which likely impacted revenue and contributed to the lower-than-expected earnings. Such incidents can lead to production delays, increased costs, and a decrease in efficiency, all of which can negatively affect profitability.
3. **Cost Management**: The company's cost management efforts could also have played a role in the EPS trend change. Artivion's focus on clinical and regulatory initiatives and significant strides in key areas might have led to increased expenses that affected net income. Additionally, the company's adjusted EBITDA growth, although positive, might not have translated into equivalent increases in net income due to various cost factors.

In summary, Artivion's EPS trend change in 2024 was primarily driven by a combination of revenue shortfall, operational disruptions, and cost management factors.